Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2009 Apr;185(4):231-4.
doi: 10.1007/s00066-009-1923-x. Epub 2009 Apr 16.

Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer

Affiliations
Controlled Clinical Trial

Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer

Changlu Wang et al. Strahlenther Onkol. 2009 Apr.

Abstract

Purpose: Dose-volume histograms (DVHs) were reviewed to determine if there is an advantage of the two modalities when treating patients with non-small cell lung cancer (NSCLC).

Patients and methods: 24 stage I NSCLC patients who underwent proton-beam therapy (PBT) from June 2003 to May 2007 were included in this study. Based on the same clinical target volumes (CTVs), treatment planning was made to cover CTV within 90% isodose lines. Each patient was evaluated by two sets of DVHs, one for PBT and the other for three-dimensional conformal X-ray therapy (3D-CRT).

Results: For all patients, the 95% isodose line covered 86.4% of the CTV for PBT, and 43.2% for 3D-CRT. PBT was associated with significantly lower mean doses to the ipsilateral lung, total lung, heart, esophagus, and spinal cord than 3D-CRT. PBT offered reduced radiation doses to the lung when evaluated in terms of percentage lung volumes receiving > or = 5 Gy (V(5)), > or = 10 Gy (V(10)), and > or = 20 Gy (V(20)) when compared to 3D-CRT.

Conclusion: PBT is advantageous over 3D-CRT in reducing doses to the lung, heart, esophagus, and spinal cord in treating stage I NSCLC.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Strahlenther Onkol. 2006 Dec;182(12):696-702 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31 - PubMed
    1. Ann Intern Med. 1996 Nov 1;125(9):723-9 - PubMed
    1. Strahlenther Onkol. 2007 Dec;183 Spec No 2:3-6 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1010-5 - PubMed

Publication types

LinkOut - more resources